Originally published 2019-08-28.

Can psilocybin, the active compound in "magic mushrooms", reset the brain of someone with depression? The short answer is that "reset" is a metaphor, not a medical finding. A small 2017 Imperial College London study gave psilocybin with psychological support to people whose depression had not responded to other treatments, and found changes in brain activity alongside an improvement in mood. Several patients said they felt "reset". Larger trials since then show that psilocybin can produce rapid, sometimes substantial relief for some people, but the effect is not a cure, does not last for everyone, and the treatment carries real risks.
Here is what the original study found, what has been learned since, and why the "reset" idea is both appealing and easy to overstate.
The 2017 Imperial College study
The research, led by Robin Carhart-Harris and published in Scientific Reports in October 2017, involved 20 adults with treatment-resistant depression, meaning their illness had not improved after at least two standard courses of treatment. Each received two doses of psilocybin a week apart, first 10 mg and then 25 mg, in a calm room with trained staff present before, during and after each session.
Nineteen of the volunteers had functional MRI scans before treatment and again the day after the higher dose. The researchers compared blood flow in different brain regions and how strongly those regions communicated with one another. Participants also filled in standard depression questionnaires, and reported benefits lasting up to five weeks.
What changed in the brain
Two findings stood out. First, blood flow fell in parts of the temporal cortex, including the amygdala, an almond-shaped structure deep in the brain that is involved in processing fear, stress and other emotions. Larger reductions in amygdala blood flow went along with larger improvements in mood.
Second, the default mode network, a set of brain regions most active when we are lost in thought, daydreaming or ruminating about ourselves, showed stronger internal connections the day after treatment. Earlier work had found that psilocybin temporarily breaks up this network during the drug experience. The team proposed a simple picture: the network loosens under the drug, then knits back together afterward, perhaps in a healthier pattern. The more the network's connections were restored, the better patients tended to feel.
This is where the language of rebooting comes from. Much of the coverage compared it to restarting a computer. It is an evocative way to describe the data, but the study could only show associations, not prove that these brain changes caused the improvement.
Why the study was only a first step
The Imperial team was open about the limitations:
- Small sample. Twenty people, with nineteen scanned, cannot establish how well a treatment works.
- No control group. Everyone knew they were receiving psilocybin. Without a placebo or comparison drug, expectations and the intensive psychological support could explain part of the improvement.
- Short follow-up. Benefits were measured over weeks, not months or years.
- Hard to blind. Even in later controlled trials, most participants can tell whether they have taken a psychedelic, which makes it difficult to separate drug effects from expectation.
The researchers also warned against self-medicating. The treatment was a carefully prepared, supervised psychological process, not simply a pill.
Psilocybin versus standard antidepressants
Commentary around this research often claimed that psilocybin tackles the root causes of depression while conventional antidepressants merely blunt emotions. That goes beyond the evidence. Carhart-Harris has described a contrast he heard in interviews with patients: people treated with psilocybin often spoke of emotional release and reconnection, while some taking daily antidepressants described feeling emotionally flattened. That is a description of experiences, not a measured verdict on which treatment works better.
The head-to-head test came in 2021, when the same group published a trial in the New England Journal of Medicine comparing two doses of psilocybin with six weeks of the antidepressant escitalopram in 59 people with moderate to severe depression. On the main depression scale the trial found no significant difference between the two treatments after six weeks. Some secondary measures favoured psilocybin, but the authors said larger and longer studies were needed.
What larger trials have shown
The biggest trial at the time, published in the New England Journal of Medicine in November 2022, tested a synthetic psilocybin called COMP360 in 233 people with treatment-resistant depression. A single 25 mg dose, given with therapist support, reduced depression scores more than a 1 mg dose after three weeks; about 37% of the high-dose group responded and 29% were in remission. By 12 weeks the advantage was no longer statistically significant. Some participants in every group reported suicidal thoughts or self-harm, a reminder that the people in these studies are seriously unwell and that the experience can be destabilising.
In the United States, the Food and Drug Administration gave psilocybin "breakthrough therapy" status in 2018 for treatment-resistant depression and in 2019 for major depressive disorder, which speeds up review but is not approval. Australia has allowed specially authorised psychiatrists to prescribe it for treatment-resistant depression since July 2023, and Oregon and Colorado have set up regulated psilocybin services. In most countries it remains an illegal drug outside research.
Common myths about magic mushrooms and depression
- "One trip cures depression." Trials show that some people improve quickly, but many relapse within weeks or months, and some do not respond at all.
- "It's natural, so it's safe." Psilocybin can cause panic, frightening experiences, confusion and raised blood pressure and heart rate. People with a personal or family history of psychosis or bipolar disorder are usually excluded from trials because of the risk of triggering symptoms.
- "The trip is the treatment." In studies, preparation, a safe setting and follow-up sessions with trained therapists are a core part of the process.
- "Wild mushrooms are an easy substitute." The potency of wild or illegally sold mushrooms varies greatly, and some poisonous species look similar.
If you are living with depression and are curious about psilocybin, the safest step is to talk to a doctor, who can explain current treatment options and whether any regulated research is open to you. If you are in crisis, contact local emergency services or a crisis line straight away.
Sources: Carhart-Harris et al., Scientific Reports, 2017; Imperial College London press release via EurekAlert!; CNN via KTVZ, 2 November 2022; Wikipedia, Psilocybin therapy; earlier coverage by The Mind Unleashed and Vice Tonic; photo by Sebastian Kaulitzki.

COMMENTS